Tonix Pharmaceuticals announced that the Company will deliver an oral presentation and present two posters at the American Society of Clinical Psychopharmacology, ASCP, Annual Meeting being held May 28-31, 2024 at the Loews Miami Beach Hotel in Miami Beach, Fla. The oral presentation will detail findings of studies of Tonmya in fibromyalgia. One poster will describe the Phase 2 proof of concept study of TNX-102 SL in fibromyalgia-type Long COVID. The second poster will describe the upcoming investigator-initiated Phase 2 trial of TNX-102 SL in treating acute stress disorder and preventing posttraumatic stress disorder after motor vehicle collision, which will be conducted by the University of North Carolina, the sponsor of the study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
- Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
- Tonix Pharmaceuticals reports Q4 EPS (86c), consensus ($1.64)
- Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering